ARIX BIOSCIENCE PLC — Director's Dealing 2020

Mar 16, 2020

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

Arix Bioscience Plc - Director/PDMR Shareholding

PR Newswire

London, March 13

ARIX BIOSCIENCE PLC

Director/PDMR Shareholding

LONDON, 13 March 2020: Arix Bioscience plc (LSE:ARIX) ("Arix"), a global venture capital company focused on investing in and building breakthrough biotech companies, today announces a conditional share award to Jonathan Peacock, Chairman, relating to his service in 2019 as an Executive Director.  The award is subject to performance conditions over a three year assessment period, consistent with the awards made to other Executive Directors in 2019, as detailed on page 70 of the Annual Report and Accounts.

PDMR DEALING NOTIFICATION
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Jonathan Peacock
2	Reason for the notification
a)	Position / status	Chairman
b)	Initial notification / Amendment	Initial Notification
3	Details of issuer
a)	Name	Arix Bioscience plc
b)	LEI	213800OVT3AHQCXNIX43
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument	Ordinary Shares of Arix Bioscience plc
Identification code	GB00BD045071
b)	Nature of the transaction	Conditional share award
c)	Price(s) and volume(s)	Price(s)	Volume(s)
Nil	231,348
d)	Aggregated information	Aggregated price	Aggregated volume
N/A (single transaction)	N/A (single transaction)
e)	Date of the transaction	12 March 2020
f)	Place of the transaction	Outside a trading venue

For further information:

Robert Lyne    Chief Operating Officer and General Counsel           +44 (0)207 290 1050

- Ends -